Advice
in the absence of a submission from the holder of the marketing authorisation:
doravirine / lamivudine / tenofovir disoproxil (Delstrigo) is not recommended for use within NHSScotland.
Indication under review: Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice357KB (PDF)
Medicine details
- Medicine name:
- doravirine/lamivudine/tenofovir disoproxil (Delstrigo)
- SMC ID:
- SMC2163
- Indication:
- Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 February 2019